

(I)

in the general formula (I), n, R_1 and R_2 are as defined in claim 2.

6. The method according to claim 5, wherein the sulfonating reagent is chlorosulfonic acid; sulfonation temperature is 45-85°C, preferably 60-75°C; reaction time is 1.5-4.5 hours, preferably 2-3.5 hours, most preferably 3 hours; and/or, the reducing agent is sodium borohydride, sodium cyanoborohydride, nickel-hydride reagents or halogen-based reducing agents.

7. Use of the polygulonic acid sulfate or pharmaceutically acceptable salt thereof according to any one of claims 1-4 in the preparation of a medicament for inhibiting tumor growth and/or metastasis.

8. The use according to claim 7, wherein the tumor is selected from the group consisting of liver cancer, stomach cancer, colorectal cancer, lung cancer, breast cancer, pancreas cancer, kidney cancer, bladder cancer, prostate cancer, melanoma, and brain cancer.

9. ~~Use of the~~The polygulonic acid sulfate or pharmaceutically acceptable salt thereof according to any one of claims 1-4 for use as ~~in the preparation of~~ tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerising factor activity inhibitors and/or actin-aggregation inhibitors.

10. A pharmaceutical composition comprising a therapeutically effective amount of the polygulonic acid sulfate or pharmaceutically acceptable salt thereof according to any one of claims 1-4.

11. Use of the pharmaceutical composition according to claim 10 in the preparation of a medicament for inhibiting tumor growth and/or metastasis ~~inhibitors~~.

12. ~~Use of the~~The pharmaceutical composition according to claim 10 for use as ~~in the preparation of~~ tumor growth inhibitors, tumor metastasis inhibitors, angiogenesis inhibitors, heparanase inhibitors, C-Met enzyme inhibitors, microtubule polymerization inhibitors, actin-depolymerising factor activity inhibitors and/or actin-aggregation inhibitors.